\-\ Texto\\:\\ \ \(0\)\
\-\ not\\ available\\.\ \(14\)\
\-\ serum\\ calcium\\ concentrations\\ must\\ be\\ periodically\\ and\\ carefully\\ monitored\\.\\ \\ phosphorus\\ replacement\\ and\\ vitamin\\ d\\ replacement\\ with\\ calcitriol\\ are\\ used\\ as\\ the\\ mainstays\\ of\\ treatment\\.\\ \\ amiloride\\ and\\ hydrochlorothiazide\\ are\\ also\\ administered\\ to\\ enhance\\ calcium\\ reabsorption\\ and\\ to\\ reduce\\ the\\ risk\\ of\\ nephrocalcinosis\\.\ \(0\)\
\-\ sonographic\\ images\\ through\\ both\\ kidneys\\ demonstrate\\ multiple\\ areas\\ of\\ increased\\ echogenicity\\ involving\\ the\\ medullary\\ pyramids\\.\\ the\\ remaining\\ renal\\ cortex\\ is\\ normal\\ in\\ echogenicity\\.\\ there\\ is\\ no\\ evidence\\ of\\ hydronephrosis\\ or\\ focal\\ mass\\ lesions\\.\ \(0\)\
\-\ medullary\\ nephrocalcinosis\\ secondary\\ to\\ hypophosphatemic\\ rickets\ \(0\)\
\-\ causes\\ of\\ medullary\\ nephrocalcinosis\\:\ \(1\)\
\-\ hyperparathyroidism\ \(35\)\
\-\ hypercalciuria\ \(4\)\
\-\ hypercalcemia\ \(21\)\
\-\ medullary\\ sponge\\ kidney\ \(4\)\
\-\ renal\\ tubular\\ acidosis\ \(5\)\
\-\ milk\\-alkali\\ syndrome\ \(0\)\
\-\ cushing\\ syndrome\ \(0\)\
\-\ bony\\ metastases\ \(2\)\
\-\ hyperthyroidism\ \(31\)\
\-\ hypothyroidism\ \(39\)\
\-\ sarcoidosis\ \(108\)\
\-\ furosemide\\ therapy\ \(0\)\
\-\ vitamin\\ d\\ and\\ phosphorus\\ therapy\\ in\\ hypophosphatemic\\ rickets\ \(0\)\
\-\ this\\ nine\\ year\\ old\\ boy\\ presents\\ with\\ a\\ history\\ of\\ hypophosphatemic\\ rickets\\.\ \(0\)\
\-\ x\\-linked\\ hypophosphatemic\\ rickets\\ is\\ a\\ congenital\\ metabolic\\ bone\\ disease\\ produced\\ by\\ a\\ urinary\\ phosphate\\ leak\\.\\ \\ vitamin\\ d\\ and\\ oral\\ phosphate\\ supplementation\\ therapy\\ is\\ useful\\ in\\ the\\ treatment\\ of\\ this\\ disease\\.\\ \\ medullary\\ nephrocalcinosis\\ may\\ occur\\ in\\ 33\\ to\\ 50\\%\\ of\\ patients\\ with\\ x\\-linked\\ hypophosphatemic\\ rickets\\ treated\\ with\\ vitamin\\ d\\ and\\ phosphate\\ therapy\\.\\ \\ the\\ medullary\\ nephrocalcinosis\\ is\\ due\\ to\\ hypercalcemia\\ and\\ hypercalciuria\\ resulting\\ from\\ the\\ treatment\\.\\ \\ the\\ treatment\\ and\\ medullary\\ nephrocalcinosis\\ alone\\ have\\ not\\ been\\ associated\\ with\\ impaired\\ renal\\ function\\.\\ \\ however\\,\\ if\\ secondary\\ hyperparathyroidism\\ develops\\,\\ increased\\ medullary\\ and\\ cortical\\ echogenicity\\ may\\ be\\ seen\\ with\\ impaired\\ renal\\ function\\.\\ \\ \ \(0\)\
\-\ references\\:\ \(0\)\
\-\ 1\\.\\ \\ middleton\\ wd\\,\\ kurtz\\ ab\\,\\ hertzberg\\ bs\\.\\ \\ ultrasound\\:\\ the\\ requisites\\.\\ 2nd\\ ed\\.\\ \\ st\\.\\ louis\\,\\ mo\\:\\ mosby\\,\\ inc\\.\\ 2004\\:\\ 136\\.\ \(0\)\
\-\ 2\\.\\ \\ brant\\ we\\.\\ \\ the\\ core\\ curriculum\\.\\ ultrasound\\.\\ philadelphia\\,\\ pa\\:\\ lippincott\\ williams\\ \\&\\ wilkins\\.\\ 2001\\:\\ 115\\.\ \(0\)\
\-\ 3\\.\\ \\ townsend\\ rr\\,\\ et\\ al\\.\\ \\ acr\\ ultrasound\\ cd\\-rom\\ series\\ learning\\ file\\.\\ \\ 2nd\\ ed\\.\\ \\ reston\\,\\ virginia\\:\\ american\\ college\\ of\\ radiology\\.\\ 2003\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ hypophosphatemic\\:\\ 0\\.3750287197061729\ \(0\)\
\-\ nephrocalcinosis\\:\\ 0\\.341640420913512\ \(0\)\
\-\ medullary\\:\\ 0\\.3318404632651579\ \(0\)\
\-\ rickets\\:\\ 0\\.25855471751208603\ \(0\)\
\-\ vitamin\\:\\ 0\\.19690230934513986\ \(0\)\
\-\ phosphate\\:\\ 0\\.18082146447255218\ \(0\)\
\-\ echogenicity\\:\\ 0\\.13732056356183553\ \(0\)\
\-\ hypercalciuria\\:\\ 0\\.13194581409348657\ \(0\)\
\-\ phosphorus\\:\\ 0\\.12054764298170145\ \(0\)\
\-\ renal\\:\\ 0\\.11682761192514428\ \(0\)\
\-\ hypercalcemia\\:\\ 0\\.10984932578435505\ \(0\)\
\-\ therapy\\:\\ 0\\.10779186478909218\ \(0\)\
\-\ impaired\\:\\ 0\\.10661460499755929\ \(0\)\
\-\ and\\:\\ 0\\.09691625278632589\ \(0\)\
\-\ the\\:\\ 0\\.09358553071712014\ \(0\)\
\-\ treatment\\:\\ 0\\.08936673414037276\ \(0\)\
\-\ hyperparathyroidism\\:\\ 0\\.0893512408123264\ \(0\)\
\-\ ultrasound\\:\\ 0\\.08678918770841916\ \(0\)\
\-\ 2nd\\:\\ 0\\.08584711787754142\ \(0\)\
\-\ calcium\\:\\ 0\\.0847236704266638\ \(0\)\
\-\ replacement\\:\\ 0\\.08426473594434503\ \(0\)\
\-\ of\\:\\ 0\\.08260578208353365\ \(0\)\
\-\ function\\:\\ 0\\.07592513226126203\ \(0\)\
\-\ ed\\:\\ 0\\.0750408286249294\ \(0\)\
\-\ amiloride\\:\\ 0\\.07500574394123459\ \(0\)\
\-\ kurtz\\:\\ 0\\.07500574394123459\ \(0\)\
\-\ hertzberg\\:\\ 0\\.07500574394123459\ \(0\)\
\-\ reston\\:\\ 0\\.07500574394123459\ \(0\)\
\-\ calcitriol\\:\\ 0\\.07167199260263586\ \(0\)\
\-\ curriculum\\:\\ 0\\.07167199260263586\ \(0\)\
\-\ townsend\\:\\ 0\\.07167199260263586\ \(0\)\
\-\ mainstays\\:\\ 0\\.06930665838534202\ \(0\)\
\-\ virginia\\:\\ 0\\.06747196262973346\ \(0\)\
\-\ hydrochlorothiazide\\:\\ 0\\.06597290704674329\ \(0\)\
\-\ reabsorption\\:\\ 0\\.06597290704674329\ \(0\)\
\-\ is\\:\\ 0\\.0642215020497837\ \(0\)\
\-\ middleton\\:\\ 0\\.06360757282944947\ \(0\)\
\-\ wd\\:\\ 0\\.06360757282944947\ \(0\)\
\-\ acr\\:\\ 0\\.06360757282944947\ \(0\)\
\-\ learning\\:\\ 0\\.06360757282944947\ \(0\)\
\-\ periodically\\:\\ 0\\.06263915570814456\ \(0\)\
\-\ concentrations\\:\\ 0\\.06177287707384089\ \(0\)\
\-\ furosemide\\:\\ 0\\.06177287707384089\ \(0\)\
\-\ cushing\\:\\ 0\\.060273821490850726\ \(0\)\
\-\ supplementation\\:\\ 0\\.060273821490850726\ \(0\)\
\-\ file\\:\\ 0\\.059615706949018105\ \(0\)\
\-\ to\\:\\ 0\\.058626441678469594\ \(0\)\
\-\ pyramids\\:\\ 0\\.05843912573524215\ \(0\)\
\-\ college\\:\\ 0\\.05843912573524215\ \(0\)\
\-\ brant\\:\\ 0\\.05741002905830977\ \(0\)\
\-\ carefully\\:\\ 0\\.05694007015225199\ \(0\)\
\-\ sponge\\:\\ 0\\.05694007015225199\ \(0\)\
\-\ syndrome\\:\\ 0\\.05655021943545194\ \(0\)\
\-\ 136\\:\\ 0\\.0564955271627822\ \(0\)\
\-\ 115\\:\\ 0\\.055672636716073476\ \(0\)\
\-\ secondary\\:\\ 0\\.05559942950066717\ \(0\)\
\-\ louis\\:\\ 0\\.05529014717186074\ \(0\)\
\-\ with\\:\\ 0\\.0551034260124298\ \(0\)\
\-\ nine\\:\\ 0\\.054924662892177525\ \(0\)\
\-\ ab\\:\\ 0\\.05423909576233975\ \(0\)\
\-\ st\\:\\ 0\\.053916621393125544\ \(0\)\
\-\ acidosis\\:\\ 0\\.05330730249877964\ \(0\)\
\-\ requisites\\:\\ 0\\.05330730249877964\ \(0\)\
\-\ inc\\:\\ 0\\.053018780176995024\ \(0\)\
\-\ hyperthyroidism\\:\\ 0\\.05274004017934959\ \(0\)\
\-\ mo\\:\\ 0\\.05220940171766434\ \(0\)\
\-\ lippincott\\:\\ 0\\.05124098459635944\ \(0\)\
\-\ wilkins\\:\\ 0\\.05101570906697531\ \(0\)\
\-\ increased\\:\\ 0\\.05072422562952522\ \(0\)\
\-\ develops\\:\\ 0\\.05058287005452681\ \(0\)\
\-\ monitored\\:\\ 0\\.05037470596205576\ \(0\)\
\-\ leak\\:\\ 0\\.05017168225266499\ \(0\)\
\-\ williams\\:\\ 0\\.049225577336284965\ \(0\)\
\-\ hypothyroidism\\:\\ 0\\.048875650379065605\ \(0\)\
\-\ mosby\\:\\ 0\\.048706117724002386\ \(0\)\
\-\ administered\\:\\ 0\\.04854001020644719\ \(0\)\
\-\ bs\\:\\ 0\\.04854001020644719\ \(0\)\
\-\ reduce\\:\\ 0\\.047756365860359605\ \(0\)\
\-\ produced\\:\\ 0\\.047756365860359605\ \(0\)\
\-\ philadelphia\\:\\ 0\\.04746269026829091\ \(0\)\
\-\ may\\:\\ 0\\.047204649402375426\ \(0\)\
\-\ core\\:\\ 0\\.047040954623457025\ \(0\)\
\-\ in\\:\\ 0\\.04667030596315816\ \(0\)\
\-\ alone\\:\\ 0\\.04613366821103325\ \(0\)\
\-\ we\\:\\ 0\\.04509735605099708\ \(0\)\
\-\ useful\\:\\ 0\\.04477904368767742\ \(0\)\
\-\ remaining\\:\\ 0\\.04457348191916197\ \(0\)\
\-\ 2001\\:\\ 0\\.04427446560428835\ \(0\)\
\-\ 2004\\:\\ 0\\.04417716219091607\ \(0\)\
\-\ hydronephrosis\\:\\ 0\\.0435264917803924\ \(0\)\
\-\ rr\\:\\ 0\\.04309136154806867\ \(0\)\
\-\ series\\:\\ 0\\.043007032168109825\ \(0\)\
\-\ metabolic\\:\\ 0\\.042518450281340416\ \(0\)\
\-\ sonographic\\:\\ 0\\.04220814770186814\ \(0\)\
\-\ 2003\\:\\ 0\\.04220814770186814\ \(0\)\
\-\ serum\\:\\ 0\\.04205728030446704\ \(0\)\
\-\ enhance\\:\\ 0\\.04198287217248401\ \(0\)\
\-\ 33\\:\\ 0\\.041273635958379455\ \(0\)\
\-\ tubular\\:\\ 0\\.040747245516664234\ \(0\)\
\-\ urinary\\:\\ 0\\.04055822472147688\ \(0\)\
\-\ kidneys\\:\\ 0\\.04037345194625956\ \(0\)\
\-\ must\\:\\ 0\\.04019274044179366\ \(0\)\
\-\ american\\:\\ 0\\.040015915509117976\ \(0\)\
\-\ sarcoidosis\\:\\ 0\\.03972940420421243\ \(0\)\
\-\ disease\\:\\ 0\\.0393751853727468\ \(0\)\
\-\ resulting\\:\\ 0\\.03902808387473316\ \(0\)\
\-\ cortex\\:\\ 0\\.03819289050418305\ \(0\)\
\-\ be\\:\\ 0\\.038052144793669765\ \(0\)\
\-\ metastases\\:\\ 0\\.03791726550656316\ \(0\)\
\-\ oral\\:\\ 0\\.037563574739495946\ \(0\)\
\-\ radiology\\:\\ 0\\.037563574739495946\ \(0\)\
\-\ references\\:\\ 0\\.0373922759921761\ \(0\)\
\-\ al\\:\\ 0\\.03726610406659869\ \(0\)\
\-\ not\\:\\ 0\\.037031210318294226\ \(0\)\
\-\ et\\:\\ 0\\.036740684292787214\ \(0\)\
\-\ bony\\:\\ 0\\.03613696052793187\ \(0\)\
\-\ pa\\:\\ 0\\.03599271046889126\ \(0\)\
\-\ are\\:\\ 0\\.035593988952805175\ \(0\)\
\-\ causes\\:\\ 0\\.035439759802281125\ \(0\)\
\-\ used\\:\\ 0\\.03511214504998666\ \(0\)\
\-\ occur\\:\\ 0\\.0344936548859011\ \(0\)\
\-\ congenital\\:\\ 0\\.03369918493921196\ \(0\)\
\-\ cortical\\:\\ 0\\.0336721831334361\ \(0\)\
\-\ risk\\:\\ 0\\.03351200840941851\ \(0\)\
\-\ kidney\\:\\ 0\\.032950035277992715\ \(0\)\
\-\ involving\\:\\ 0\\.032851860470155196\ \(0\)\
\-\ 50\\:\\ 0\\.03275484409417124\ \(0\)\
\-\ this\\:\\ 0\\.03223241507497081\ \(0\)\
\-\ boy\\:\\ 0\\.032083756643689045\ \(0\)\
\-\ areas\\:\\ 0\\.03184288064956507\ \(0\)\
\-\ available\\:\\ 0\\.03182132875657215\ \(0\)\
\-\ treated\\:\\ 0\\.02920690298128607\ \(0\)\
\-\ focal\\:\\ 0\\.028054370487750203\ \(0\)\
\-\ through\\:\\ 0\\.027919358546571005\ \(0\)\
\-\ however\\:\\ 0\\.02776021727260379\ \(0\)\
\-\ been\\:\\ 0\\.02732535785408318\ \(0\)\
\-\ if\\:\\ 0\\.027250949722100154\ \(0\)\
\-\ due\\:\\ 0\\.026959873574399964\ \(0\)\
\-\ lesions\\:\\ 0\\.026936076039786448\ \(0\)\
\-\ evidence\\:\\ 0\\.026621374058171058\ \(0\)\
\-\ patients\\:\\ 0\\.026384671087796484\ \(0\)\
\-\ both\\:\\ 0\\.026154592261959646\ \(0\)\
\-\ bone\\:\\ 0\\.025590932151774107\ \(0\)\
\-\ associated\\:\\ 0\\.024720619149151468\ \(0\)\
\-\ demonstrate\\:\\ 0\\.02438280124046705\ \(0\)\
\-\ have\\:\\ 0\\.023429882790045636\ \(0\)\
\-\ multiple\\:\\ 0\\.022940555105963455\ \(0\)\
\-\ presents\\:\\ 0\\.022562052973307576\ \(0\)\
\-\ seen\\:\\ 0\\.022080856738092715\ \(0\)\
\-\ also\\:\\ 0\\.022061131716711226\ \(0\)\
\-\ images\\:\\ 0\\.021695076402373538\ \(0\)\
\-\ by\\:\\ 0\\.019917106346837004\ \(0\)\
\-\ normal\\:\\ 0\\.01914957688684992\ \(0\)\
\-\ as\\:\\ 0\\.018842005882973887\ \(0\)\
\-\ there\\:\\ 0\\.01866196998962118\ \(0\)\
\-\ from\\:\\ 0\\.0186272960638241\ \(0\)\
\-\ history\\:\\ 0\\.01791909651273524\ \(0\)\
\-\ mass\\:\\ 0\\.01791512930278175\ \(0\)\
\-\ or\\:\\ 0\\.01631620430786927\ \(0\)\
\-\ no\\:\\ 0\\.015251841228453545\ \(0\)\
\-\ year\\:\\ 0\\.01445412562442858\ \(0\)\
\-\ old\\:\\ 0\\.013880964019204075\ \(0\)\
